Poly Medicure’s board has approved the unaudited financial results for Q3 (Oct-Dec) and nine months ended December 31, 2025. The Nomination & Remuneration Committee approved the grant of 2,000 stock options to eligible employees under the Poly Medicure Limited Employee Stock Option Scheme 2020. Results are consolidated & standalone. Meeting started at 12:45 PM and ended at 02:35 PM.
Q3 Financial Results Approved
The Board of Directors has approved the unaudited financial results, both consolidated and standalone, for the third quarter (Q3: Oct-Dec) and nine months ending December 31, 2025. This decision was made during a board meeting held on February 5, 2026.
Financial Performance Highlights
Here are some key figures from the standalone results for the quarter ended December 31, 2025 (in lacs):
- Revenue from operations: ₹41,886.15
- Total Income: ₹44,841.37
- Profit before tax: ₹10,601.48
- Profit after tax: ₹7,838.38
ESOP Grant Approved
The Nomination & Remuneration Committee has approved a grant of 2,000 stock options under the Poly Medicure Limited Employee Stock Option Scheme 2020 to eligible employees. The exercise price for options is INR 100/-. Vesting will occur over 4 years after a one year period from the grant date.
Source: BSE
